Impact of donor hepatitis C virus on kidney transplant outcomes for hepatitis C positive recipients in the direct acting antiviral era: time to revise the kidney donor risk index?
Kidneys from donors with hepatitis C (HCV) infection are traditionally considered to be at risk for poorer survival outcomes, as reflected in the KDPI. Modern direct acting antivirals (DAAs) may modify this risk. Using UNOS data, HCV infected adult first time kidney transplant recipients from 2014-2017 were examined. Graft and patient survival were compared in a propensity matched cohort of recipients of HCV antibody(+) kidneys versus antibody(-) kidneys. Subsequent analysis was performed in a propensity matched cohort of recipients of HCV viremic (RNA positive) vs. HCV naive kidneys. There were 379 recipients each in the matched cohort of recipients of HCV antibody(+) vs. HCV antibody(-) kidneys. Despite a higher KDPI (58.2% for HCV antibody(+) vs. 38.8% for HCV antibody(-)), 1 year patient and graft survival were similar in the HCV(+) and HCV(-) groups (95.4% and 94.9% vs 97.9% and 96.0%, p=0.543 and p=0.834, respectively). There were 200 recipients each in the cohort of recipients of HCV viremic vs. HCV naïve kidneys, with the KDPI again higher in the HCV viremic group (56.8% vs 35.2%). Baseline hazard ratios for graft failure (HR 4.69; p=0.009) and death (HR 7.60; p=0.003) were significantly elevated in the viremic group, but crossed 1 at 21 and 24 months, respectively. In the modern DAA era, calculated likely KDPI overestimates risk kidneys from HCV antibody(+) donors. Donor viremia conveys an early risk which appears to subside over time. These results suggest that it may be time to revise the kidney donor risk index.